Video Experimental Relacionado
Updated: Oct 22, 2025
12:40
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
15.0K
Estado actual y futuro de los inhibidores de JAK
Donal P McLornan1, Janet E Pope2, Jason Gotlib3
1Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Lancet (London, England)
|August 29, 2021
Resumen
Los inhibidores de Janus kinase (JAK) están revolucionando los tratamientos para varias enfermedades al dirigirse a las vías de señalización JAK-STAT. Esta revisión resume sus éxitos y seguridad, explorando futuros desarrollos terapéuticos.
Área de la Ciencia:
- Ciencias biomédicas
- Farmacología
- Inmunología
Sus antecedentes:
- Las vías de Janus kinase (JAK) y transductor de señales y activador de la transcripción (STAT) son cruciales en numerosos procesos de enfermedad.
- La orientación terapéutica de estas vías con inhibidores JAK ha demostrado una utilidad clínica significativa.
Objetivo del estudio:
- Revisar los datos actuales sobre la eficacia y seguridad de varios inhibidores de JAK.
- Discutir las direcciones futuras y los avances potenciales en las terapias basadas en inhibidores de JAK.
Principales métodos:
- Revisión de la literatura de estudios clínicos y datos terapéuticos sobre los inhibidores de la JAK.
- Síntesis de información sobre el éxito del tratamiento y los efectos adversos.
- Análisis hipotético de futuras investigaciones y aplicaciones clínicas.
Principales resultados:
- Los inhibidores de JAK han demostrado un éxito significativo en el tratamiento de neoplasias mieloproliferativas, artritis reumatoide, enfermedad inflamatoria intestinal y afecciones dermatológicas.
- Los perfiles de seguridad de los inhibidores de JAK disponibles están generalmente bien caracterizados, con efectos secundarios específicos observados para cada agente.
- Se ha logrado una rápida traducción de la investigación básica a la aplicación clínica.
Conclusiones:
- Los inhibidores de JAK representan un avance terapéutico importante en múltiples áreas de la enfermedad.
- La investigación continua es esencial para optimizar el tratamiento con inhibidores de JAK y explorar nuevas aplicaciones.
- La comprensión de la señalización JAK-STAT sigue siendo crítica para el desarrollo de terapias dirigidas de próxima generación.
Videos de Conceptos Relacionados
01:20The JAK-STAT Signaling Pathway
9.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.6K
02:34Inhibition of Cdk Activity
5.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K
01:23Dipeptidyl Peptidase 4 Inhibitors
300
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
300
01:16Therapeutic Drug Monitoring: Overview and Classification
48
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
48
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
251
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
251
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K